

# BIOFILM CONTROL IN DRUG MANUFACTURING



Lucia Clontz and Carmen M. Wagner  
Editors

# **Biofilm Control in Drug Manufacturing**

**Lucia Clontz and Carmen M. Wagner  
Editors**

**PDA  
Bethesda, MD, USA  
DHI Publishing, LLC  
River Grove, IL, USA**

[www.pda.org/bookstore](http://www.pda.org/bookstore)

10 9 8 7 6 5 4 3 2 1

**ISBN: 1-933722-64-9**

**Copyright © 2012 Lucia Clontz and Carmen M. Wagner**

**All rights reserved.**

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted in any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in the book. The authors have made every effort to provide accurate citations. If there are any omissions, please contact the publisher.

While every effort has been made by the publisher and the authors to ensure the accuracy of the information expressed in this book, the organization accepts no responsibility for errors or omissions. The views expressed in this book are those of the editors and authors and may not represent those of either Davis Healthcare International or the PDA, its officers, or directors.



*Connecting People, Science and Regulation®*



This book is printed on sustainable resource paper approved by the Forest Stewardship Council. The printer, Gasch Printing, is a member of the Green Press Initiative and all paper used is from SFI (Sustainable Forest Initiative) certified mills.

**PDA**

4350 East West Highway  
Suite 200  
Bethesda, MD 20814  
United States  
[www.pda.org/bookstore](http://www.pda.org/bookstore)  
001-301-986-0293

**Davis Healthcare International Publishing, LLC**

2636 West Street  
River Grove  
IL 60171  
United States  
[www.DHIBooks.com](http://www.DHIBooks.com)

[www.pda.org/bookstore](http://www.pda.org/bookstore)

---

---

# CONTENTS

## PREFACE

xv

## I THE CONTAMINATION CONTROL BY DESIGN (CCbD©) MODEL — A PROACTIVE APPROACH TO CONTAMINATION CONTROL

I

*Carmen M. Wagner*

Control of Microbial Contamination in Drug Manufacturing	1
GMP regulations and contamination control	3
Development of the (CCbD©) concept	5
Relationship between CCbD©, QbD, RM and PAT	7
Quality management and QbD	10
Quality risk management	11
Process Analytical Technology (PAT)	15
The Contamination Control by Design (CCbD©) Model	16
Composition of the CCbD© model	17
CCbD© model elements	18
Knowledge and understanding	19
Risk assessment	21
Quality systems and documentation	22
Process Analytical Technology	22

iii

Controlling the sources of contamination	23
Personnel controls	23
Raw materials controls	24
Process controls	24
Facility and clean utilities controls	25
Equipment controls	25
Monitoring and continuous improvement	26
Conclusion	27
References and Additional Reading	29
About the Author	32
Appendix: Regulatory Framework	33
<b>2 BIOFILM BASICS</b>	<b>37</b>
<i>Paul J. Sturman</i>	
Introduction	37
Biofilm Formation, Growth and Maturity	40
Conditioning film deposition	42
Initial cell migration to surface and attachment	42
Permanent cell attachment and growth	43
Biofilm maturation and detachment	43
Biofilm Processes	44
Concentration gradients	45
Microbial community development	45
Genetic transfer in biofilms	46
Quorum sensing in biofilms	47
The Biofilm Matrix	47
Extracellular matrix composition	48
Biofilm morphology	49
The viscoelastic nature of biofilms	49
Detecting and Measuring Biofilms	50
Planktonic organism sampling	51
Biofilm sampling	51
Indirect assessment of biofilm	52
Why Biofilms are Hard to Kill	52
Slow penetration of antimicrobials	53
Altered microenvironments	54
Stress response and antimicrobial treatment	54
Persister cells	55
Biofilm Control Strategies	56
Physical control strategies	56
Chemical control strategies	57
Oxidizing biocides	58

Non-oxidizing biocides	59
Biofilm removal agents	59
Quorum-sensing blockers	60
Anti-biofilm coatings/imbedded antimicrobials	61
Biological control strategies	61
Nutrient removal	63
Application method and design strategies	63
Conclusion	64
References	65
About the Author	72
<b>3 MICROBIAL CONTAMINATION CONTROL CONSIDERATIONS IN BIOPHARMACEUTICAL PRODUCTION</b>	<b>75</b>
<i>Lucia Clontz</i>	
Introduction	75
Microbial Contamination Control	77
Biofilm Formation and Dispersion	80
Initial cell adhesion to surfaces	81
Surface roughness	81
Surface chemical composition	82
Biofilm formation in liquid environments	84
Biofilm dispersion	85
Equipment — Contamination Risks and Control	86
Equipment design	86
Sanitary design	87
Cleaning and decontamination	88
Cleaning validation	88
Cleaning verification	90
Microbial cleaning specifications	91
Sanitization and sterilization	91
Equipment soft parts	92
Bioprocessing equipment	94
UF/DF systems	96
Chromatography systems	101
Contamination control strategies	104
Single-use technology	107
Biofilm Impact on Products and Business	109
Conclusion	112
References	113
About the Author	116

<b>4</b>	<b>ESTABLISHING MICROBIAL CONTAMINATION CONTROL IN DRUG MANUFACTURING THROUGH RISK MANAGEMENT</b>	<b>117</b>
	<i>Karen Zink McCullough</i>	
	Introduction	117
	Risk Management	119
	Product Design and Development: Establishing Control	
	Measures for Bioburden and Endotoxin	121
	The importance of product requirements in the initial assignment of microbial limits	121
	Microbiological risk assessment	125
	Risk assessment tools	125
	Method development	128
	Building design	130
	Process development	136
	Validation/Qualification of Systems/Processes:	
	Demonstrating Control of Bioburden and Endotoxin	136
	Facility cleaning and disinfection	137
	Equipment cleaning and sanitization	138
	Facility air and compressed gases	139
	Personnel	140
	Water systems	142
	Process Validation: Critical Control Points for Bioburden and Endotoxin Control	143
	In-process limits or levels	147
	Routine Monitoring: Demonstrating Continued Control of Bioburden and Endotoxin	148
	Operators	148
	Monitoring of air and surfaces	149
	Testing of raw materials and in-process samples	151
	Data trending	153
	Responding to nonconformances and excursions	155
	Post Production Assessment of Microbiological Control	156
	Summary	157
	References	157
	About the Author	163
<b>5</b>	<b>CONTROLLING BIOFILMS IN DRUG MANUFACTURING EQUIPMENT</b>	<b>165</b>
	<i>Mark Pasmore and Robert Fry</i>	
	Introduction	165
	Biofilm Development	166

Ranking Biofilm Control	168
Manufacturing Systems	169
Systems and equipment design	171
Water distribution systems	171
Pharmaceutical/biopharmaceutical processing and filling equipment	172
Mixing/filling tanks	172
Pumps	175
Piping	176
Filters (microbial retentive)	177
Particulate filters/screens	178
Fill nozzles	178
Additional design considerations	179
Equipment cleanability	179
Materials of construction	180
Facility air quality	181
Single-use/disposable systems and components	181
Biofilm Prevention — System/Equipment Maintenance	182
Biofilm Control — Microbial Detection	184
Current methods for microbial monitoring	185
Biofilm detection	185
Biofilm Control — Equipment Cleaning	188
Cleaning/sanitization program	190
Trough/automatic parts washer cleaning	192
Storage of cleaned equipment	193
Equipment passivation	194
Effects of cleaning on materials	194
Biofilm Control — Differences/Similarities in Non-Sterile, Terminally Sterilized, and Aseptic Manufacturing	195
Biofilm Control — Validation	197
Biofilm Remediation	198
Conclusion	200
References	200
About the Authors	203

**6 INVESTIGATING THE LINK BETWEEN CONTAMINATION IN THE MANUFACTURING ENVIRONMENT AND PATIENT SAFETY 205**

<i>Mark Hunter, Michelle Luebke and Mark Pasmore</i>	
Patient 1	206
Patient 2	206
Infection	207



Sepsis	209
Signs and symptoms of infection/sepsis	210
Patient risk factors	214
Infection/sepsis — the perfect storm	216
Investigation — the causal continuum	218
Intrinsic continuum	220
Extrinsic continuum	221
Manufacturing contamination impacts on patients	225
Microbial Contamination in the Manufacturing Environment	225
Non-sterile, terminally sterilized, aseptically filled	227
Proliferation	228
Ingress	229
Biofilms as an elevated risk	230
Conclusions	231
References	232
About the Authors	236

## **7 DETECTION, PREVENTION AND CONTROL OF BIOFILMS IN PHARMACEUTICAL WATER SYSTEMS 239**

<i>Teri C. Soli</i>	
Introduction	239
Biofilm Impact	241
Biofilm Detection	242
Purpose	242
Historical approach/confusion	243
New understanding of biofilm	244
Planktonic proportionality	244
Localized effects	245
Impracticality of surface monitoring in pharmaceutical water systems	246
Flow interruption, system opening, and new component installation	246
Non-similar flow and topography	248
Process control and ideal planktonic sampling	250
Challenges of planktonic sampling permanent connections	252
Speciation and objectionable microorganisms	253
Biofilm Prevention	258
Water system design	258
Materials of construction	259
Tank level controls, vent filters, and rupture disks	261

Loops	261
Dead legs	263
Point-of-use valves	265
Point-of-use connectors	267
Sampling ports	268
Flush water disposal	270
Water system unit operations	271
In-line ultraviolet units	271
TOC reducers	274
Ozone destruction	275
Micro-retentive filters	276
Ultrafilters and nanofilters	278
Polishing deionizers	279
In-line UV unit in combination with downstream filter	279
Biofilm Control — Water System Maintenance	280
Multi-media or sand filters	281
Water softeners	281
Activated carbon beds	282
Ultraviolet lights	283
Filters	285
Reverse osmosis units	286
Deionizers	288
Twin bed deionizers	290
Mixed bed deionizers	290
Electro-deionizers	291
Ultrafilters	292
In-line/on-line instrumentation	293
Biofilm Control — Routine Sanitization	293
Hot water sanitization	293
Chemical sanitization	296
Heating“pasteurization”	297
Continuous tank ozonation	298
Conclusion	298
References	299
About the Author	301

**8 BIOFILM DETECTION AND DATA MANAGEMENT 303**

<i>Teri C. Soli</i>	
Introduction	303
Biofilm Detection	304
Conventional cultivation-dependent methods	306
Metabolic condition of bacteria	307

Effect of growth medium composition	308
Alternative microbiological methods	315
Cultivation-dependent RMM methods	316
Non-cultivation dependent methods	319
Efficacy Monitoring	322
The value of data trending	323
Alert levels, action levels, and specifications	323
Control/Remediation	325
Root cause investigation	326
CAPA	328
Conclusion	330
References	331
About the Author	332
<b>9</b>	
<b>EARLY DETECTION AND PREVENTION OF BIOFILMS IN PROCESS EQUIPMENT</b>	<b>333</b>
<i>Mark Fornalik</i>	
Introduction	333
Fouling/Biofouling: A Primer	335
Detecting and Characterizing Biofilms	339
Removable coupons: fouling cell technology	339
Assessment tools: surface analytical science	341
Detecting wall fouling	344
Preventing and Remediating Biofilms	345
Mechanical Cleaning: Water Flush Optimization	346
Chemical Cleaning: Optimizing CIP	347
Choice of chemical cleaner	348
Chemical cleaner concentration and temperature	351
Surface tension and incorporating surfactants into chemical cleaning	353
Case Studies by the Author	354
High-purity water biofouling	355
Industrial salt water system	357
Bioprocessing operation	360
Large-scale brewery	362
Conclusion	365
References	369
About the Author	372

<b>10 SANITIZATION APPROACHES FOR BIOFILM CONTROL</b>	<b>373</b>
<i>Teri C. Soli</i>	
Introduction	373
Heat Sanitization	374
Hot water	374
Pure steam	377
Chemical Sanitization	380
Sanitizer efficacy	382
Oxidizing Sanitizers	383
Chemical concentration	385
Chlorine	386
Alkaline solution	387
Partially neutralized solution	388
Precautions and issues	388
Non-chlorine halogens	389
Ozone	389
Precautions and issues	391
Peracetic acid	393
Precautions and issues	394
Hydrogen peroxide	394
Precautions and issues	395
Chlorine dioxide	396
Precautions and issues	397
Proprietary Mixtures	397
Hydrogen peroxide + peracetic acid + acetic acid	397
Precautions and issues	398
Alkaline peroxide + quat + chelator	399
Precautions and issues	400
Cleanroom disinfectants	401
Quaternary ammonium compounds (quats)	401
Phenolics	402
Formaldehyde	402
Glutaraldehyde	402
Acids and caustics	402
Passivating/derouging agents	403
Overview of Keys to Effective Sanitization	403
Sanitize frequently	404
Kill and remove biofilm	404
Use an effective sanitizer	404
Use an effective procedure	405
Minimize recolonization	405

Conclusion	406
References	406
About the Author	408

## **II DISINFECTANT EFFICACY STUDIES USING BIOFILM REACTORS 409**

<i>Lucia Clontz</i>	
Introduction	409
Flow-through Biofilm Reactors	412
The Flow Cell System	413
The Drip Flow Biofilm Reactor	413
The Rotating Disc Reactor	414
The Annular Reactor	415
The CDC Biofilm Reactor	416
Static Biofilm Reactors	417
Colony biofilm assay	418
Microtiter plate biofilm assay	418
The MBEC™ assay	419
The HTP Assay™	420
Factors that Impact Disinfectant Efficacy Studies	421
Choosing a Biofilm Reactor	423
Testing Disinfectants Using the CDC Biofilm Reactor	424
Setting up the CDC Biofilm Reactor	425
Inoculating the CDC Biofilm Reactor	426
Operating the CDC Biofilm Reactor	426
Exposure of biofilm to disinfectants	427
Harvesting and enumerating biofilm cells	428
Testing Disinfectants Using Microtiter Plates	429
Biofilm assay	430
Crystal violet reporter assay	430
Viable cell density determination	431
Biofilm inhibition determination	432
Disinfectant efficacy determination	432
Determination of biofilm removal	432
Determination of antimicrobial efficacy	433
Disinfectant Efficacy Evaluation	433
Method Validation	434
Conclusion	435
References	436
About the Author	438

<b>CONCLUSION</b>	<b>441</b>
<i>Lucia Clontz and Carmen M. Wagner</i>	
Future Trends in Biofilm Prevention, Control, and Remediation	442
References	444
About the Authors	445
<b>APPENDIX</b>	<b>447</b>
Organizations with Special Focus on Biofilm	
Education/Discussion	447
Companies that Provide Consulting, Products, and/or Services in the Area of Biofilms	450
<i>Glossary</i>	457
<i>Index</i>	469



---

---

## PREFACE

Microbial contamination of pharmaceutical products continues to be frequently cited as a reason for product recalls, manufacturing problems, and product rejection. Microbial contamination is costly to manage, time consuming to investigate and often difficult to determine root cause. The frequency of such problems, as well as the cost and investment of time and resources required to address them, support the need to develop and implement better microbial control programs that can more effectively prevent contamination from occurring.

As you will learn in various chapters in this book, biofilms are a preferred way of life for microbes and they are not only responsible for contamination in pharmaceutical and biopharmaceutical processing but also for many human pathogeneses including chronic wounds, device-associated infections, and various nosocomial infections and diseases in patients with compromised immune systems (Wilson, 2001). In fact, as reported in Infection Research (Kerksiek, 2008) estimates of the frequency of infections caused by biofilms (bacterial and/or fungal) lie between 65% (Centers for Disease Control and Prevention/CDC) and 80% (National Institute



of Health). In drug manufacturing, biofilms are known to impact equipment and systems, such as those used for water and product purification (e.g., filtration and chromatography). In addition, biofilms may lead to product adulteration, which can potentially cause patient harm. Therefore, understanding how microorganisms develop into biofilm cells, and the mechanisms of antimicrobial resistance present in biofilm communities, is critical for successfully controlling microbial contamination in drug manufacturing.

Over the years, many studies have been carried out in the areas of biofilm eradication, remediation, and prevention. However, the realization that biofilms are ubiquitous in nature and extremely difficult to destroy resulted in a shift in paradigm — from microbial eradication and remediation to biofilm prevention. Chapters 1, 4, 6, and 7 specifically address the importance of risk assessment and a proactive, rather than reactive, microbial control program.

On a molecular level, studies have been performed to better understand biofilm development. For example, in an article published in the *Journal of Bacteriology* (Branda et al., 2004), studies with *Bacillus subtilis* provided valuable information regarding the genetic control of biofilm formation, and showed that spore formation, long thought to be a process involving only single cells, is actually closely associated with the development of multicellular communities. There is particular interest on gene expression responsible for production of extra polymeric substances (EPS) and cell signaling/quorum sensing, both associated with biofilm establishment and growth (Hansen et al., 2007; Gonzales and Keshavan, 2006). Other studies include research with cyclic-di-GMP (c-di-GMP), which is a key player in the decision between motile planktonic and sessile microbial lifestyle. One study evaluated a chemosensory system that regulates biofilm formation through modulation of cyclic diguanylate levels (Hickman et al., 2005). Data suggested that increased c-di-GMP levels enhance biofilm formation, while decreased c-di-GMP levels prevent initiation of biofilm development. Researchers are also attempting to gain greater understanding of “persister” cells, which are specialized dormant cells proposed as the main reason for the refractory nature of biofilm infections (Keren et al., 2004). Chapters 2, 3, and 8 explain in further detail some of these ideas.

In terms of contamination control, the literature describes approaches to biofilm removal and prevention that range from the use of enzymes that can remove most, but not all, types of biofilms (Orgaz et al., 2007) to antimicrobial surfaces (Danese, 2002). Chapters 10 and 11 address sanitization approaches and studies in biofilm remediation and control.

Given the fact that the first step in biofilm formation is actually the ability to attach to a surface, and not microcolony formation or production of an EPS matrix, it is critical to investigate biological pathways used by bacteria to detect the presence of surfaces. Although the initial contact with a surface is not necessarily regulated and may happen by chance, there is evidence that formation of a stable cell-surface interaction may be genetically regulated (Stanley and Lazazzera, 2004). This is an important finding, because if surface attachment can be controlled, or even prevented, then all the other pathways to complete biofilm formation would be negated. Chapters 2, 5, and 9 help shed some light on these topics.

It is clear that biofilms are responsible for a number of serious contamination challenges in pharmaceutical/biopharmaceutical manufacturing, and the cause of several medical problems including chronic infections and medical device related infections. These complex and highly structured communities are difficult to prevent and even more difficult to eradicate. This book reviews the status of biofilm knowledge, management and control in pharmaceuticals, and is the first attempt to gather this type of information.

We close the book with an Appendix on resources that can be used by readers as a guide to general information about biofilms and related products.

A special note of gratitude goes to the authors who worked diligently to help make this book an excellent source of information for the pharmaceutical professional working in this area. Special thanks as well to our colleagues, associates, vendors and others who encouraged us and provided direct or indirect input to our work. We also would like to recognize Amy Davis — without her constant guidance and encouragement, this book would not be

possible. Last but not least, we would like to thank our spouses, Jim Clontz and Brian Wagner, for their constant support, endurance and patience as we deprived them of our company many nights, holidays and weekends, to complete the book in a timely manner. Thank you, all.

*Lucia Clontz and Carmen M. Wagner*